Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation

Abstract

Observational clinical and ex vivo studies have established a strong association between atrial fibrillation and inflammation1. However, whether inflammation is the cause or the consequence of atrial fibrillation and which specific inflammatory mediators may increase the atria's susceptibility to fibrillation remain elusive. Here we provide experimental and clinical evidence for the mechanistic involvement of myeloperoxidase (MPO), a heme enzyme abundantly expressed by neutrophils, in the pathophysiology of atrial fibrillation. MPO-deficient mice pretreated with angiotensin II (AngII) to provoke leukocyte activation showed lower atrial tissue abundance of the MPO product 3-chlorotyrosine, reduced activity of matrix metalloproteinases and blunted atrial fibrosis as compared to wild-type mice. Upon right atrial electrophysiological stimulation, MPO-deficient mice were protected from atrial fibrillation, which was reversed when MPO was restored. Humans with atrial fibrillation had higher plasma concentrations of MPO and a larger MPO burden in right atrial tissue as compared to individuals devoid of atrial fibrillation. In the atria, MPO colocalized with markedly increased formation of 3-chlorotyrosine. Our data demonstrate that MPO is a crucial prerequisite for structural remodeling of the myocardium, leading to an increased vulnerability to atrial fibrillation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mpo−/− mice show less atrial fibrosis, reduced matrix metalloproteinase activity and lower chlorotyrosine bioavailability after AngII treatment.
Figure 2: Analysis of atrial fibrillation inducibility in Mpo−/− and WT mice in vivo.
Figure 3: Epicardial mapping of Langendorff-perfused hearts of AngII- or saline (vehicle)-treated WT or Mpo−/− mice.
Figure 4: Atrial MPO amounts and protein-bound 3-chlorotyrosine in individuals with or without atrial fibrillation.

Similar content being viewed by others

References

  1. Issac, T.T., Dokainish, H. & Lakkis, N.M. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J. Am. Coll. Cardiol. 50, 2021–2028 (2007).

    Article  CAS  Google Scholar 

  2. Kannel, W.B., Wolf, P.A., Benjamin, E.J. & Levy, D. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. 82, 2N–9N (1998).

    Article  CAS  Google Scholar 

  3. Nattel, S. & Opie, L.H. Controversies in atrial fibrillation. Lancet 367, 262–272 (2006).

    Article  Google Scholar 

  4. Kannel, W.B., Abbott, R.D., Savage, D.D. & McNamara, P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N. Engl. J. Med. 306, 1018–1022 (1982).

    Article  CAS  Google Scholar 

  5. Aviles, R.J. et al. Inflammation as a risk factor for atrial fibrillation. Circulation 108, 3006–3010 (2003).

    Article  Google Scholar 

  6. Sata, N. et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn. Heart J. 45, 441–445 (2004).

    Article  Google Scholar 

  7. Conway, D.S., Buggins, P., Hughes, E. & Lip, G.Y. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am. Heart J. 148, 462–466 (2004).

    Article  CAS  Google Scholar 

  8. Fontes, M.L., Mathew, J.P., Rinder, H.M., Zelterman, D., Smith, B.R. & Rinder, C.S. et al. Atrial fibrillation after cardiac surgery/cardiopulmonary bypass is associated with monocyte activation. Anesth. Analg. 101, 17–23 (2005).

    Article  Google Scholar 

  9. Frustaci, A. et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96, 1180–1184 (1997).

    Article  CAS  Google Scholar 

  10. Nakamura, Y. et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb. Res. 111, 137–142 (2003).

    Article  CAS  Google Scholar 

  11. Chen, C.L. et al. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J. Mol. Cell. Cardiol. 45, 742–753 (2008).

    Article  CAS  Google Scholar 

  12. Fu, X., Kassim, S.Y., Parks, W.C. & Heinecke, J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem. 276, 41279–41287 (2001).

    Article  CAS  Google Scholar 

  13. Fu, X., Kassim, S.Y., Parks, W.C. & Heinecke, J.W. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J. Biol. Chem. 278, 28403–28409 (2003).

    Article  CAS  Google Scholar 

  14. Baldus, S. et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J. Clin. Invest. 108, 1759–1770 (2001).

    Article  CAS  Google Scholar 

  15. Lin, C.S. & Pan, C.H. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell. Mol. Life Sci. 65, 1489–1508 (2008).

    Article  CAS  Google Scholar 

  16. Casaclang-Verzosa, G., Gersh, B.J. & Tsang, T.S. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J. Am. Coll. Cardiol. 51, 1–11 (2008).

    Article  Google Scholar 

  17. Burstein, B. & Nattel, S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol. 51, 802–809 (2008).

    Article  CAS  Google Scholar 

  18. Xiao, H.D. et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia and sudden death. Am. J. Pathol. 165, 1019–1032 (2004).

    Article  CAS  Google Scholar 

  19. Roell, W. et al. Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 450, 819–824 (2007).

    Article  CAS  Google Scholar 

  20. Verheule, S. et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ. Res. 94, 1458–1465 (2004).

    Article  CAS  Google Scholar 

  21. Schrickel, J.W. et al. Enhanced heterogeneity of myocardial conduction and severe cardiac electrical instability in annexin A7-deficient mice. Cardiovasc. Res. 76, 257–268 (2007).

    Article  CAS  Google Scholar 

  22. El Bekay, R. et al. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-κB. Blood 102, 662–671 (2003).

    Article  CAS  Google Scholar 

  23. Abu-Soud, H.M. & Hazen, S.L. Nitric oxide is a physiological substrate for mammalian peroxidases. J. Biol. Chem. 275, 37524–37532 (2000).

    Article  CAS  Google Scholar 

  24. Eiserich, J.P. et al. Formation of nitric oxide–derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391, 393–397 (1998).

    Article  CAS  Google Scholar 

  25. Burstein, B., Qi, X.Y., Yeh, Y.H., Calderone, A. & Nattel, S. Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: A novel consideration in atrial remodeling. Cardiovasc. Res. 76, 442–452 (2007).

    Article  CAS  Google Scholar 

  26. Polyakova, V., Miyagawa, S., Szalay, Z., Risteli, J. & Kostin, S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J. Cell. Mol. Med. 12, 189–208 (2008).

    Article  CAS  Google Scholar 

  27. Rossi, M.A. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J. Hypertens. 16, 1031–1041 (1998).

    Article  CAS  Google Scholar 

  28. Hazen, S.L. & Heinecke, J.W. 3-chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99, 2075–2081 (1997).

    Article  CAS  Google Scholar 

  29. Mihm, M.J. et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104, 174–180 (2001).

    Article  CAS  Google Scholar 

  30. Desrochers, P.E., Mookhtiar, K., Van Wart, H.E., Hasty, K.A. & Weiss, S.J. Proteolytic inactivation of α1-proteinase inhibitor and alpha 1-antichymotrypsin by oxidatively activated human neutrophil metalloproteinases. J. Biol. Chem. 267, 5005–5012 (1992).

    CAS  PubMed  Google Scholar 

  31. Wang, Y. et al. Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation. J. Biol. Chem. 282, 31826–31834 (2007).

    Article  CAS  Google Scholar 

  32. Schrickel, J.W. et al. Induction of atrial fibrillation in mice by rapid transesophageal atrial pacing. Basic Res. Cardiol. 97, 452–460 (2002).

    Article  Google Scholar 

  33. Schwoerer, A.P. et al. Mechanical unloading of the rat heart involves marked changes in the protein kinase-phosphatase balance. J. Mol. Cell. Cardiol. 45, 846–852 (2008).

    Article  CAS  Google Scholar 

  34. Zheng, L. et al. Apolipoprotein AI is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114, 529–541 (2004).

    Article  CAS  Google Scholar 

  35. Lang, C. et al. Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enterovirus myocarditis. J. Mol. Med. 86, 49–60 (2008).

    Article  CAS  Google Scholar 

  36. Butz, G.M. & Davisson, R.L. Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol. Genomics 5, 89–97 (2001).

    Article  CAS  Google Scholar 

  37. Cheitlin, M.D. et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 108, 1146–1162 (2003).

    Article  Google Scholar 

Download references

Acknowledgements

We wish to thank H. Wieboldt for expert technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (BA 1870/3-2 and BA 1870/7-1 to S.B., Ru 1472/1-1 to T.K.R. and SFB-TR19 to K.K.), the US National Institutes of Health (P01 HL076491-055328 and P01 HL087018-02001 to S.H.), the Deutsche Herzstiftung (to V.R. and R.P.A.) and the Werner Otto Stiftung (to S.B.).

Author information

Authors and Affiliations

Authors

Contributions

V.R. designed the project, performed experiments, performed statistical analysis and wrote the manuscript. T.K.R. performed experiments and prepared the manuscript. K.F., A.K., K. Sydow, D.L., E.-C.v.L. and K. Szoecs performed experiments. R.P.A., J.W.S., T.L. and G.N. were responsible for the design and the performance of the electrophysiological studies in mice. B.H.-H., A.P.S., A.S. and H.E. were responsible for the radiotelemetric measurements in mice and cellular electrophysiology. X.F. and S.L.H. were responsible for mass spectrometry analysis. M.D. performed the echocardiography in mice. H.T. provided human atrial tissue. K.K. was responsible for the fibrosis analysis. U.W., W.-H.Z., R.H.B., H.R., T.M., T.E., H.E., S.L.H., B.A.F. and S.W. provided suggestions on the project and revised the manuscript. S.B. supervised the project and wrote the manuscript.

Corresponding author

Correspondence to Stephan Baldus.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1–5 and Supplementary Tables 1–3 (PDF 3532 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rudolph, V., Andrié, R., Rudolph, T. et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 16, 470–474 (2010). https://doi.org/10.1038/nm.2124

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2124

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing